Related references
Note: Only part of the references are listed.Interpretation of Cytochrome P-450 Inhibition and Induction Effects From Clinical Data: Current Standards and Recommendations for Implementation
Stephen M. Stout et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2021)
Impact of CYP2D6 on serum concentrations of flupentixol, haloperidol, perphenazine and zuclopenthixol
Ragnhild Birkeland Waade et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2021)
Association of CYP2C19 and CYP2D6 Poor and Intermediate Metabolizer Status With Antidepressant and Antipsychotic Exposure A Systematic Review and Meta-analysis
Filip Milosavljevic et al.
JAMA PSYCHIATRY (2021)
Drug-Drug Interactions at Organic Cation Transporter 1
Shiwei Zhou et al.
FRONTIERS IN PHARMACOLOGY (2021)
Review and Consensus on Pharmacogenomic Testing in Psychiatry
Chad A. Bousman et al.
PHARMACOPSYCHIATRY (2021)
Can haloperidol prophylaxis reduce the incidence of delirium in critically ill patients in intensive care units? A systematic review and meta-analysis
Ping Lin et al.
HEART & LUNG (2020)
Haloperidol in palliative care: Indications and risks
Iwona Zaporowska-Stachowiak et al.
BIOMEDICINE & PHARMACOTHERAPY (2020)
Clinically Relevant Interactions between Atypical Antipsychotics and Anti-Infective Agents
Edoardo Spina et al.
PHARMACEUTICALS (2020)
Why Do You Keep Telling Me That Drug-Drug Interactions Are Important in Psychopharmacology When I Do Not See Them in My Clinical Practice? My Failure to Convince Clinicians
Jose de Leon
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2019)
Association of Delirium Response and Safety of Pharmacological Interventions for the Management and Prevention of Delirium A Network Meta-analysis
Yi-Cheng Wu et al.
JAMA PSYCHIATRY (2019)
A comprehensive review of the clinical utility of and a combined analysis of the clozapine/norclozapine ratio in therapeutic drug monitoring for adult patients
Georgios Schoretsanitis et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2019)
Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis
Maximilian Huhn et al.
LANCET (2019)
Validation and Clinical Utility of the hERG IC50:Cmax Ratio to Determine the Risk of Drug-Induced Torsades de Pointes: A Meta-Analysis
David F. Lehmann et al.
PHARMACOTHERAPY (2018)
Possible Pharmacodynamic and Pharmacokinetic Drug-Drug Interactions That Are Likely to Be Clinically Relevant and/or Frequent in Bipolar Disorder
Jose de Leon et al.
CURRENT PSYCHIATRY REPORTS (2018)
A systematic review and combined analysis of therapeutic drug monitoring studies for oral paliperidone
Georgios Schoretsanitis et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2018)
Haloperidol serum concentrations in critically ill patients included in the REDUCE study
Anne W. van Schijndel et al.
INTENSIVE CARE MEDICINE (2018)
A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting paliperidone
Georgios Schoretsanitis et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2018)
Possible Oxcarbazepine Inductive Effects on Aripiprazole Metabolism: A Case Report
Ian R. McGrane et al.
JOURNAL OF PHARMACY PRACTICE (2018)
International trends in antipsychotic use: A study in 16 countries, 2005-2014
Oskar Halfdanarson et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2017)
A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting risperidone
Georgios Schoretsanitis et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2017)
Potentially Clinically Relevant Pharmacodynamic Interactions Between Antiepileptic Drugs and Psychotropic Drugs: An Update
Edoardo Spina et al.
CURRENT PHARMACEUTICAL DESIGN (2017)
Genotype and co-medication dependent CYP2D6 metabolic activity: effects on serum concentrations of aripiprazole, haloperidol, risperidone, paliperidone and zuclopenthixol
Patteet Lisbeth et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Assessing drug-drug interactions through therapeutic drug monitoring when administering oral second-generation antipsychotics
Edoardo Spina et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2016)
Pharmacokinetic considerations and recommendations in palliative care, with focus on morphine, midazolam and haloperidol
L. G. Franken et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2016)
Clinically significant pharmacokinetic drug interactions of antiepileptic drugs with new antidepressants and new antipsychotics
Edoardo Spina et al.
PHARMACOLOGICAL RESEARCH (2016)
The Role of Abcb5 Alleles in Susceptibility to Haloperidol-Induced Toxicity in Mice and Humans
Ming Zheng et al.
PLOS MEDICINE (2015)
The effects of antiepileptic inducers in neuropsychopharmacology, a neglected issue. Part 1: A summary of the current state for clinicians
Jose de Leon
REVISTA DE PSIQUIATRIA Y SALUD MENTAL (2015)
Pharmacogenetics of CYP2B6, CYP2A6 and UGT2B7 in HIV treatment in African populations: focus on efavirenz and nevirapine
Antoinette Colic et al.
DRUG METABOLISM REVIEWS (2015)
A network meta-analysis on comparative efficacy and all-cause discontinuation of antimanic treatments in acute bipolar mania
A. Yildiz et al.
PSYCHOLOGICAL MEDICINE (2015)
Clinically relevant interactions between newer antidepressants and second-generation antipsychotics
Edoardo Spina et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2014)
Neuropathogenesis of Delirium: Review of Current Etiologic Theories and Common Pathways
Jose R. Maldonado
AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY (2013)
Estimating Dopamine D2 Receptor Occupancy for Doses of 8 Antipsychotics A Meta-Analysis
Irene M. Lako et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2013)
Interactions between antiepileptics and second-generation antipsychotics
Jose de Leon et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2012)
Evidence-Based Medicine Versus Personalized Medicine Are They Enemies?
Jose de Leon
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2012)
Human UDP-Glucuronosyltransferase Isoforms Involved in Haloperidol Glucuronidation and Quantitative Estimation of Their Contribution
Yukiko Kato et al.
DRUG METABOLISM AND DISPOSITION (2012)
Perpetrators of pharmacokinetic drug-drug interactions arising from altered cytochrome P450 activity: a criteria-based assessment
Thomas M. Polasek et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Paying Attention to Pharmacokinetic and Pharmacodynamic Mechanisms to Progress in the Area of Anticholinergic Use in Geriatric Patients
J. de Leon
CURRENT DRUG METABOLISM (2011)
Highlights of Drug Package Inserts and the Website DailyMed The Need for Further Improvement in Package Inserts to Help Busy Prescribers
Jose de Leon
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2011)
Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis
Andrea Cipriani et al.
LANCET (2011)
The consolidation of neuroleptic therapy: Janssen, the discovery of haloperidol and its introduction into clinical practice
Francisco Lopez-Munoz et al.
BRAIN RESEARCH BULLETIN (2009)
A Meta-Analysis of the Risk of Acute Extrapyramidal Symptoms With Intramuscular Antipsychotics for the Treatment of Agitation
Theodore D. Satterthwaite et al.
JOURNAL OF CLINICAL PSYCHIATRY (2008)
Haloperidol is an inhibitor but not substrate for MDR1/P-glycoprotein
Koichi Iwaki et al.
JOURNAL OF PHARMACY AND PHARMACOLOGY (2006)
Cytochrome P450-mediated metabolism of haloperidol and reduced haloperidol to pyridinium metabolites
Kathryn M. Avent et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2006)
Combined effects of itraconazole and CYP2D6*10 genetic polymorphism on the pharmacokinetics and pharmacodynamics of haloperidol in healthy subjects
JY Park et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2006)
Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP4502C19
J De Leon et al.
PSYCHOSOMATICS (2006)
Pharmacogenetics of antidepressants and antipsychotics:: the contribution of allelic variations to the phenotype of drug response
J Kirchheiner et al.
MOLECULAR PSYCHIATRY (2004)
A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition
EP Harrigan et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2004)
Haloperidol half-life after chronic dosing
J de Leon et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2004)
Fluvoxamine dose-dependent interaction with haloperidol and the effects on negative symptoms in schizophrenia
N Yasui-Furukori et al.
PSYCHOPHARMACOLOGY (2004)
Significant dose effect of carbamazepine on reduction of steady-state plasma concentration of haloperidol in schizophrenic patients
N Yasui-Furukori et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2003)
Fluoxetine augmentation of haloperidol in chronic schizophrenia
JC Shim et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2003)
Effects of smoking and cytochrome P450 2D6*10 allele on the plasma haloperidol concentration/dose ratio
K Ohara et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2003)
Histamine H1-receptor antagonists, promethazine and homochlorcyclizine, increase the steady-state plasma concentrations of haloperidol and reduced haloperidol
A Suzuki et al.
THERAPEUTIC DRUG MONITORING (2003)
Glucuronidation enzymes, genes and psychiatry
J de Leon
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2003)
The safety and pharmacokinetics of quetiapine when coadministered with haloperidol, risperidone, or thioridazine
SG Potkin et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2002)
Potent inhibition of CYP2D6 by haloperidol metabolites: stereoselective inhibition by reduced haloperidol
JG Shin et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2001)
Importance of the cytochrome P450 2D6 genotype for the drug metabolic interaction between chlorpromazine and haloperidol
Y Suzuki et al.
THERAPEUTIC DRUG MONITORING (2001)
Binding of antipsychotic drugs to human brain receptors - Focus on newer generation compounds
E Richelson et al.
LIFE SCIENCES (2000)
Effect of a genetic polymorphism of CYP1A2 inducibility on the steady state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients with schizophrenia
K Mihara et al.
THERAPEUTIC DRUG MONITORING (2000)
Share Paper
